Ποια είναι η τιμή για Heidelberg Pharma AG (HPHA)

Η τιμή για Heidelberg Pharma AG (HPHA) είναι $2.99

Ποια είναι η κεφαλαιοποίηση αγοράς για Heidelberg Pharma AG (HPHA)

Η κεφαλαιοποίηση αγοράς για Heidelberg Pharma AG (HPHA) είναι $139.84M

Heidelberg Pharma AG (HPHA) Τιμή και Κεφαλαιοποίηση Αγοράς

Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.

Η τιμή για HPHA	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$110,133 $139.84M	NVDA	$5.152T	+3,684,359.38%
$96,977.21 $139.84M	AAPL	$4.537T	+3,244,249.43%
$89,101.65 $139.84M	GOOG	$4.169T	+2,980,774.60%
$77,853.95 $139.84M	MSFT	$3.642T	+2,604,485.26%
$59,949.55 $139.84M	AMZN	$2.805T	+2,005,497.91%

Η τιμή για HPHA

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$110,133 $139.84M